Cargando…

Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies

OBJECTIVE: Physiological and/or psychological problems that affect the quality of life of the patients occur depending on the diagnosis and treatment of hematological malignancies. Cancer treatment causes sexual problems such as infertility, vaginal dryness, and erectile dysfunction in the patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Karacan, Yasemin, Yildiz, Hicran, Demircioglu, Burcin, Ali, Ridvan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785071/
https://www.ncbi.nlm.nih.gov/pubmed/33426190
http://dx.doi.org/10.4103/apjon.apjon_40_20
_version_ 1783632384764149760
author Karacan, Yasemin
Yildiz, Hicran
Demircioglu, Burcin
Ali, Ridvan
author_facet Karacan, Yasemin
Yildiz, Hicran
Demircioglu, Burcin
Ali, Ridvan
author_sort Karacan, Yasemin
collection PubMed
description OBJECTIVE: Physiological and/or psychological problems that affect the quality of life of the patients occur depending on the diagnosis and treatment of hematological malignancies. Cancer treatment causes sexual problems such as infertility, vaginal dryness, and erectile dysfunction in the patients. Erectile dysfunction and loss of sexual desire are the most common sexual problems of men, while dyspareunia and loss of sexual desire are the most common sexual problems of women. This descriptive study was carried out to evaluate sexual problems and affecting factors in the patients with hematological cancer. METHODS: Between July 1, 2011, and July 31, 2011, 45 sexually active patients who volunteered to participate in the study and whose written consents were obtained were included in the study. The data of the study were collected using the descriptive characteristics form prepared by the researchers based on the relevant literature and the Arizona Sexual Experiences Scale (ASEX). The scale scores range from 5 to 30 and a score of >11 above indicates sexual dysfunction. RESULTS: Sexual dysfunction was observed in 62.2% of the patients. About 80.0% of women and 57.1% of men had sexual dysfunction. Sexual dysfunction was observed to be highest between the ages of 52–71 (81.2%) years. The mean total ASEX score was 15.90 ± 4.25 in women and 13.34 ± 5.37 in men. The ability to reach orgasm subscale score was found to differ by gender in the ASEX scale (P < 0.05). CONCLUSIONS: The prevalence of sexual dysfunction is high in the patients with hematological malignancies. It is recommended to evaluate these patients in terms of the presence of sexual dysfunction, as in the patients with other chronic diseases.
format Online
Article
Text
id pubmed-7785071
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-77850712021-01-07 Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies Karacan, Yasemin Yildiz, Hicran Demircioglu, Burcin Ali, Ridvan Asia Pac J Oncol Nurs Original Article OBJECTIVE: Physiological and/or psychological problems that affect the quality of life of the patients occur depending on the diagnosis and treatment of hematological malignancies. Cancer treatment causes sexual problems such as infertility, vaginal dryness, and erectile dysfunction in the patients. Erectile dysfunction and loss of sexual desire are the most common sexual problems of men, while dyspareunia and loss of sexual desire are the most common sexual problems of women. This descriptive study was carried out to evaluate sexual problems and affecting factors in the patients with hematological cancer. METHODS: Between July 1, 2011, and July 31, 2011, 45 sexually active patients who volunteered to participate in the study and whose written consents were obtained were included in the study. The data of the study were collected using the descriptive characteristics form prepared by the researchers based on the relevant literature and the Arizona Sexual Experiences Scale (ASEX). The scale scores range from 5 to 30 and a score of >11 above indicates sexual dysfunction. RESULTS: Sexual dysfunction was observed in 62.2% of the patients. About 80.0% of women and 57.1% of men had sexual dysfunction. Sexual dysfunction was observed to be highest between the ages of 52–71 (81.2%) years. The mean total ASEX score was 15.90 ± 4.25 in women and 13.34 ± 5.37 in men. The ability to reach orgasm subscale score was found to differ by gender in the ASEX scale (P < 0.05). CONCLUSIONS: The prevalence of sexual dysfunction is high in the patients with hematological malignancies. It is recommended to evaluate these patients in terms of the presence of sexual dysfunction, as in the patients with other chronic diseases. Wolters Kluwer - Medknow 2020-10-15 /pmc/articles/PMC7785071/ /pubmed/33426190 http://dx.doi.org/10.4103/apjon.apjon_40_20 Text en Copyright: © 2020 Ann & Joshua Medical Publishing Co. Ltd http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Karacan, Yasemin
Yildiz, Hicran
Demircioglu, Burcin
Ali, Ridvan
Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
title Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
title_full Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
title_fullStr Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
title_full_unstemmed Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
title_short Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
title_sort evaluation of sexual dysfunction in patients with hematological malignancies
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785071/
https://www.ncbi.nlm.nih.gov/pubmed/33426190
http://dx.doi.org/10.4103/apjon.apjon_40_20
work_keys_str_mv AT karacanyasemin evaluationofsexualdysfunctioninpatientswithhematologicalmalignancies
AT yildizhicran evaluationofsexualdysfunctioninpatientswithhematologicalmalignancies
AT demirciogluburcin evaluationofsexualdysfunctioninpatientswithhematologicalmalignancies
AT aliridvan evaluationofsexualdysfunctioninpatientswithhematologicalmalignancies